• Recently, analysts signaled that Clorox is expected to report June-quarter earnings of US$1.64 per share, a year-over-year decline of 42.9%, on revenues of US$1.91 billion, down 4.1%, with limited indications of an earnings beat.
• This sharp expected earnings decline, combined with a weak Earnings ESP and Zacks Rank of 4, highlights growing skepticism around the strength of Clorox’s near-term profit trajectory ahead of its August 3 earnings call.
• Against this backdrop of anticipated earnings and revenue declines, we’ll examine how softer analyst expectations influence Clorox’s existing investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Clorox Investment Narrative Recap

To own Clorox, you generally have to believe its core household and cleaning brands can remain relevant and profitable despite slower categories, pricing pressure, and shifting consumer preferences. The latest expectation for a steep 42.9% year-over-year EPS decline and softer revenue for the June quarter does not change the long-term brand thesis on its own, but it does sharpen the near term focus on margin resilience and the risk that consumer demand and competition could weigh more heavily on profits than previously thought.

The most relevant recent development here is Clorox’s April 30 update cutting fiscal 2026 guidance, with net sales now expected to fall about 6% and EPS guided to US$4.78 to US$4.98, down roughly a quarter year over year. Against that backdrop, the projected June quarter earnings drop reinforces existing concerns around cost pressures, category sluggishness, and competitive discounting, and raises the stakes for upcoming product innovation and ERP benefits to show up in results more convincingly.

Yet behind the familiar brand story, there is a less obvious risk investors should be aware of around...

Clorox's narrative projects $7.9 billion revenue and $886.0 million earnings by 2029. This requires 5.5% yearly revenue growth and a $130.0 million earnings increase from $756.0 million today.

Uncover how Clorox's forecasts yield a $105.29 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already assuming only about US$7.9 billion of revenue and roughly US$800.7 million of earnings by 2029, which is a much more pessimistic path than the baseline view and could look more or less reasonable once we see how this weaker near term earnings picture and the risk of rising environmental and regulatory costs reshape expectations.

Explore 6 other fair value estimates on Clorox - why the stock might be worth 21% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Clorox research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Clorox research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clorox's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.